MERLIN TIMI 36

OBJECTIVE: To evaluate a novel anti-ischemic agent, ranolazine, in patients with acute coronary syndromes.

View/Download
_______________________________________________________________________________

1. Evaluation of a novel anti-ischemic agent in acute coronary syndromes: design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, Skene A, McCabe CH, Braunwald E. Am Heart J 2006;151:1186 e1-9.
   | Abstract | Request Reprints |
   

2. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, et al. JAMA 2007;297:1775-83.
   | Abstract | Request Reprints |
   

3. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Scirica BM, Morrow DA, Hod H, et al. Circulation 2007;116:1647-52.
   | Abstract | Request Reprints |
   

4. Prospective evaluation of the prognostic implications of low level elevation of cardiac troponin using a new highly-sensitive assay for cardiac troponin I: results from the MERLIN-TIMI 36 trial. Bonaca MP, Scirica BM, Sabatine MS, Dalby A, Spinar J, Melanson S, Jarolim P, Morrow DA. Circulation 2007; 116 (16 Suppl II) :II-381.
   | Request Reprints |
   
   
5. Anti-ischemic effects of ranolazine in women: results from the randomized, placebo-controlled MERLIN-TIMI 36 trial. Mega JL, Hochman JS, Scirica BM, Murphy SA, McCabe CH, Merlini P, Niguarda O, Morrow DA. . Circulation 2007; 116 (16 Suppl II) :II-538.
   | Request Reprints |
   
   
6. Effects of ranolazine on disease-specific health status and quality of life: results from the MERLIN-TIMI 36 Randomized Trial. Arnold SV, Morrow DA, Wang K, Lei Y, Mahoney EM, Kempf JA, Scirica BM, Cohen DJ. J Am Coll Cardiol 2008;51:A215.
   | Request Reprints |
   
   
7. Myeloperoxidase levels associated with risk of cardiovascular death and heart failure after non-ST elevation acute coronary syndrome. Scirica BM, Sabatine MS, Jarolim P, Sloan S, Murphy SA, de Lemos JL, Morrow DA. J Am Coll Cardiol 2008;51:A218.
   | Request Reprints |
   
   
8. Chronic kidney disease, cardiovascular outcomes, and treatment disparities following non-ST elevation myocardial infarction. Mega JL, Scirica BM, Qin J, Gibson CM, Morrow DA. J Am Coll Cardiol 2008;51:A220.
   | Request Reprints |
   
   
9. Efficacy and safety of randolazine in chronic angina: observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI 36 trial. Wilson SR, Morrow DA, Scirica BM, Murphy SA, Buros JL, McCabe CH, Braunwald E. J Am Coll Cardiol 2008;51:A225.
   | Request Reprints |